Bio-Path Holdings, Inc. (NASDAQ:BPTH)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Thursday.

Other analysts also recently issued research reports about the stock. Maxim Group set a $2.00 target price on shares of Bio-Path Holdings and gave the company a “buy” rating in a research report on Wednesday, April 5th. Zacks Investment Research downgraded shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.

Bio-Path Holdings (BPTH) opened at 0.404 on Thursday. The company’s market cap is $38.64 million. Bio-Path Holdings has a 52 week low of $0.33 and a 52 week high of $1.75. The stock has a 50 day moving average of $0.39 and a 200 day moving average of $0.69.

Bio-Path Holdings (NASDAQ:BPTH) last released its earnings results on Thursday, May 11th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Equities research analysts predict that Bio-Path Holdings will post ($0.07) earnings per share for the current fiscal year.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/20/bio-path-holdings-inc-nasdaqbpth-stock-rating-reaffirmed-by-hc-wainwright.html.

A number of hedge funds have recently added to or reduced their stakes in BPTH. Bank of New York Mellon Corp boosted its position in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. Sabby Management LLC boosted its position in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the last quarter. HighTower Advisors LLC boosted its position in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the first quarter worth about $105,000. 19.88% of the stock is owned by institutional investors and hedge funds.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.